These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 12607793

  • 1. Lansoprazole in adolescents with gastroesophageal reflux disease: pharmacokinetics, pharmacodynamics, symptom relief efficacy, and tolerability.
    Gunasekaran T, Gupta S, Gremse D, Karol M, Pan WJ, Chiu YL, Keith R, Fitzgerald J.
    J Pediatr Gastroenterol Nutr; 2002; 35 Suppl 4():S327-35. PubMed ID: 12607793
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics and pharmacodynamics of lansoprazole in children with gastroesophageal reflux disease.
    Gremse D, Winter H, Tolia V, Gunasekaran T, Pan WJ, Karol M, Chiu YL, Pilmer B, Book L.
    J Pediatr Gastroenterol Nutr; 2002; 35 Suppl 4():S319-26. PubMed ID: 12607792
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of lansoprazole in adolescents with symptomatic erosive and non-erosive gastroesophageal reflux disease.
    Fiedorek S, Tolia V, Gold BD, Huang B, Stolle J, Lee C, Gremse D.
    J Pediatr Gastroenterol Nutr; 2005 Mar; 40(3):319-27. PubMed ID: 15735486
    [Abstract] [Full Text] [Related]

  • 4. Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole.
    Mee AS, Rowley JL.
    Aliment Pharmacol Ther; 1996 Oct; 10(5):757-63. PubMed ID: 8899084
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children.
    Tolia V, Ferry G, Gunasekaran T, Huang B, Keith R, Book L.
    J Pediatr Gastroenterol Nutr; 2002 Oct; 35 Suppl 4():S308-18. PubMed ID: 12607791
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics and pharmacodynamics of lansoprazole in children 13 to 24 months old with gastroesophageal reflux disease.
    Heyman MB, Zhang W, Huang B, Chiu YL, Amer F, Winter HS.
    J Pediatr Gastroenterol Nutr; 2007 Jan; 44(1):35-40. PubMed ID: 17204950
    [Abstract] [Full Text] [Related]

  • 8. Safety and pharmacodynamics of lansoprazole in patients with gastroesophageal reflux disease aged <1 year.
    Springer M, Atkinson S, North J, Raanan M.
    Paediatr Drugs; 2008 Jan; 10(4):255-63. PubMed ID: 18590344
    [Abstract] [Full Text] [Related]

  • 9. Safety of lansoprazole in the treatment of gastroesophageal reflux disease in children.
    Tolia V, Fitzgerald J, Hassall E, Huang B, Pilmer B, Kane R.
    J Pediatr Gastroenterol Nutr; 2002 Jan; 35 Suppl 4():S300-7. PubMed ID: 12607790
    [Abstract] [Full Text] [Related]

  • 10. Comparison of the effect of lansoprazole and omeprazole on intragastric acidity and gastroesophageal reflux in patients with gastroesophageal reflux disease.
    Janczewska I, Sagar M, Sjöstedt S, Hammarlund B, Iwarzon M, Seensalu R.
    Scand J Gastroenterol; 1998 Dec; 33(12):1239-43. PubMed ID: 9930385
    [Abstract] [Full Text] [Related]

  • 11. Lansoprazole: in the management of gastroesophageal reflux disease in children.
    Scott LJ.
    Paediatr Drugs; 2003 Dec; 5(1):57-61; discussion 62. PubMed ID: 12513106
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children.
    Tran A, Rey E, Pons G, Pariente-Khayat A, D'Athis P, Sallerin V, Dupont C.
    Clin Pharmacol Ther; 2002 May; 71(5):359-67. PubMed ID: 12011821
    [Abstract] [Full Text] [Related]

  • 13. Age-dependent pharmacokinetics of lansoprazole in neonates and infants.
    Zhang W, Kukulka M, Witt G, Sutkowski-Markmann D, North J, Atkinson S.
    Paediatr Drugs; 2008 May; 10(4):265-74. PubMed ID: 18590345
    [Abstract] [Full Text] [Related]

  • 14. Lansoprazole: in the treatment of gastro-oesophageal reflux disease in children and adolescents.
    Croom KF, Scott LJ.
    Drugs; 2005 May; 65(15):2129-35; discussion 2136-7. PubMed ID: 16225368
    [Abstract] [Full Text] [Related]

  • 15. The effects of oral doses of lansoprazole and omeprazole on gastric pH.
    Tolman KG, Sanders SW, Buchi KN, Karol MD, Jennings DE, Ringham GL.
    J Clin Gastroenterol; 1997 Mar; 24(2):65-70. PubMed ID: 9077718
    [Abstract] [Full Text] [Related]

  • 16. Lansoprazole in children: pharmacokinetics and efficacy in reflux oesophagitis.
    Faure C, Michaud L, Shaghaghi EK, Popon M, Laurence M, Mougenot JF, Hankard R, Navarro J, Jacoz-Aigrain E.
    Aliment Pharmacol Ther; 2001 Sep; 15(9):1397-402. PubMed ID: 11552911
    [Abstract] [Full Text] [Related]

  • 17. Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously.
    Freston J, Chiu YL, Pan WJ, Lukasik N, Täubel J.
    Am J Gastroenterol; 2001 Jul; 96(7):2058-65. PubMed ID: 11467632
    [Abstract] [Full Text] [Related]

  • 18. Acid suppression in healthy subjects following lansoprazole or pantoprazole.
    Huang JQ, Goldwater DR, Thomson AB, Appelman SA, Sridhar S, James CF, Chiu YL, Pilmer BL, Keith RG, Hunt RH.
    Aliment Pharmacol Ther; 2002 Mar; 16(3):425-33. PubMed ID: 11876695
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of pantoprazole versus ranitidine in the treatment of patients with symptomatic gastroesophageal reflux disease.
    van Zyl J, van Rensburg C, Vieweg W, Fischer R.
    Digestion; 2004 Mar; 70(1):61-9. PubMed ID: 15297779
    [Abstract] [Full Text] [Related]

  • 20. Clinical and humanistic outcomes in patients with gastroesophageal reflux disease converted from omeprazole to lansoprazole.
    Nelson WW, Vermeulen LC, Geurkink EA, Ehlert DA, Reichelderfer M.
    Arch Intern Med; 2000 Sep 11; 160(16):2491-6. PubMed ID: 10979061
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.